Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis

International Journal of Clinical and Experimental Pathology

Volumn 5, Issue 6, 2012, Pages 503-511

  Alexandrescu, Sanda ^a   Tatevian, Nina ^a   Czerniak, Bogdan A ^b   Covinsky, Michael H ^a   Burns, Nadja K ^a   Brown, Robert E ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Histogenesis; Langerhans cell histiocytosis; Morphoproteomics; Osteoclastogenesis; Signaling pathway; TGF

Indexed keywords

BIOLOGICAL MARKER; GLI2 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; NUCLEAR PROTEIN; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL MEMBRANE; CELL NUCLEUS; CHILD; CYTOPLASM; FEMALE; HUMAN; IMMUNOLOGY; LANGERHANS CELL HISTIOCYTOSIS; MALE; METABOLISM; METHODOLOGY; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; PRESCHOOL CHILD; PROTEOMICS; SIGNAL TRANSDUCTION;

BIOLOGICAL MARKERS; CELL DIFFERENTIATION; CELL MEMBRANE; CELL NUCLEUS; CHILD; CHILD, PRESCHOOL; CYTOPLASM; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; NUCLEAR PROTEINS; OSTEOCLASTS; OSTEOLYSIS; PROTEOMICS; SIGNAL TRANSDUCTION; THALIDOMIDE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84866012710     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Degar BA, Rollins BJ. Langerhans cell histiocytosis: malignancy or inflammatory disorder do-ing a great job of imitating one? Disease Models and Mechanisms 2009; 2: 436-439.
2. Geissmann F, Lepelletier Y, Fraitag S, Valladeau J, Bodemer C, Debré M, Leborgne M, Saeland S, Brousse N. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood 2001; 97: 1241-1248.
3. Aricò M, Nichols K, Whitlock JA, Arceci R, Haupt R, Mittler U, Kühne T, Lombardi A, Ishii E, Egeler RM, Danesino C. Familial clustering of Lang-erhans cell histiocytosis. Br J Haematol 1999; 107: 883-888.
4. Da Costa CE, Szhuai K, van Eijk R, Hoogeboom M, Sciot R, Mertens F. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer 3009; 48: 239-249.
5. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, Kuo FC, Ligon AH, Stevenson KE, Kehoe SM, Garraway LA, Hahn WC, Meyerson M, Fleming MD, Rollins BJ. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010; DOI10.1182.
6. Fleming MD, Pinkus JL, Fournier MV, Alexander SW, Tam C, Loda M, Sallan SE, Nichols KE, Carpentieri DF, Pinkus GS, Rollins BJ. Coincident expression of the chemokine receptors CCR6 and CCR7 by pathologic Langerhans cells in Langerhans cell histiocytosis. Blood 2003; 101: 2474-2475.
7. Senechal B, Elain G, Jeziorski E, Grondin V, Patey-Mariaud de Serre N, Jaubert F, Beldjord K, Lellouch A, Glorion C, Zerah M, Mary P, Barkaoui M, Emile JF, Boccon-Gibod L, Josset P, Debré M, Fischer A, Donadieu J, Geissmann F. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med 2007; 4: e253.
8. Russell RG. Bisphosphonates: the first 40 years. Bone 2011; 49: 2-19.
9. Farran RP, Zaretski E, Egeler RM. Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol 2001; 23: 54-56.
10. Brown RE. More on pamidronate in Langerhans'-cell histiocytosis. N Engl J Med 2001; 345: 1503.
11. Kamizono J, Okada Y, Shirahata A, Tanaka Y. Bisphosphonate induces remission of refractory osteolysis in langerhans cell histiocytosis. J Bone Miner Res 2002; 17: 1926-1928.
12. Sivendran S, Harvey H, Lipton A, Drabick J. Treatment of Langerhans cell histiocytosis bone lesions with zoledronic acid: a case series. Int J Hematol 2011; 93: 782-786.
13. Tsuda H, Yamasaki H, Tsuji T. Resolution of bone lysis in Langerhans cell histiocytosis by bisphosphonate therapy. Br J Haematol 2011; 154: 287.
14. Morimoto A, Shioda Y, Imamura T, Kanegane H, Sato T, Kudo K, Nakagawa S, Nakadate H, Tauchi H, Hama A, Yasui M, Nagatoshi Y, Kinoshita A, Miyaji R, Anan T, Yabe M, Kamizono J; LCH Committee, Japanese Pediatric Leukemia/ Lymphoma Study Group. Nationwide survey of bisphosphonate therapy for children with reactivated Langerhans cell histiocytosis in Japan. Pediatr Blood Cancer 2011; 56: 110-115.
15. McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer 2007; 48: 44-49.
16. Choe JY, Jung HJ, Park KY, Kum YS, Song GG, Hyun DS, Park SH, Kim SK. Anti-fibrotic effect of thalidomide through inhibiting TGF-beta-induced ERK 1/2 pathways in bleomycin-induced lung fibrosis in mice. Inflamm Res 2010; 59: 177-188.
17. Arai H, Furusu A, Nishino T, Obata Y, Nakazawa Y, Nakazawa M, Hirose M, Abe K, Koji T, Kohno S. Thalidomide prevents the progression of peritoneal fibrosis in mice. Acta Histochem Cytochem 2011; 44: 51-60.
18. Giannopoulos K, Schmitt M, Własiuk P, Chen J, Bojarska-Junak A, Kowal M, Roliñski J, Dmoszyñska A. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia 2008; 22: 222-224.
19. Giannopoulos K, Dmoszynska A, Kowal M, Wasik-Szczepanek E, Bojarska-Junak A, Rolinski J, Döhner H, Stilgenbauer S, Bullinger L. Thalidomide exerts distinct molecular antileukemic effects and combined thalidomide/fludarabine therapy is clinically effective in high-risk chronic lymphocytic leukemia. Leukemia 2009; 23: 1771-1778.
20. Brown RE. Angiotensin-converting enzyme, transforming growth factor beta (1), and inteleukin 11 in the osteolytic lesions of Langerhans cell histiocytosis. Arch Pathol Lab Med 2000; 124: 1287-1290.
21. Kudo O, Sabokbar A Popcock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003; 32: 1-7.
22. Maier R, Ganu V, Lotz M. Interleukin-11, an inducible cytokine in human articular chondrocytes and synoviocytes, stimulates the production of the tissue inhibitor of metalloproteinases. J Biol Chem 1993; 268: 21527-21532.
23. Brown RE. Morphoproteomics: exposing protein circuitries in tumors to identify potential therapeutic targets in cancer patients. Expert Rev Proteomics 2005; 2: 337-348.
24. Brown RE. Morphogenomics and morphoproteomics: A role for Anatomic Pathology in Personalized Medicine. Arch Pathol Lab Med 2009; 133: 568-579.
25. de Graaf JH, Tamminga RY, Dam-Meiring A, Kamps WA, Timens W. The presence of cytokines in Langerhans' cell histiocytosis. J Pathol 1996; 180: 400-406.
26. Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG, Merkel AR, Oyajobi BO, Matrisian LM, Mundy GR, Sterling JA. TGF-beta promotion of Gli2-induced expression of parathyroid hormonerelated protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res 2011; 71: 822-831.
27. Kiuru M, Solomon J, Ghali B, van der Meuten M, Crystal RG, Hidaka C. Transient overexpression of sonic hedgehog alters the architecture and mechanical properties of trabecular bone. J Bone Miner Res 2009; 24: 1598-1607.
28. Gupta J, Robbins J, Jilling T, Seth P. TGFbetadependent induction of interleukin 11 and interleukin-8 involves SMAD and p38 MAPK pathways in breast tumor models with varied bone metastases potential. Cancer Biol Ther 2011; 11: 311-316.
29. Guise TA, Chirgwin JM. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clin Orthop Relat Res 2003; S32-38.
30. Dennler S, André J, Alexaki I, Li A, Magnaldo T, ten Dijke P, Wang XJ, Verrecchia F, Mauviel A.Induction of sonic hedgehog mediators by transforming growth factor-beta: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res 2007; 67: 6981-6986.
31. Nakchbandi IA, Weir EE, Insogna KL, Philbrick WM, Broadus AE. Parathyroid hormone-related protein induces spontaneous osteoclast formation via a paracrine cascade. Proc Natl Acad Sci USA 2000; 97: 7296-7300.
32. Andersson BU, Tani E, Andersson U, Henter JI. Tumor necrosis factor, interleukin 11, and leukemia inhibitory factor produced by Langerhans cells in Langerhans cell histiocytosis. J Pediatr Hematoll Oncol 2004; 26: 706-711.
33. Guk KD, Kuprash DV. Interleukin-11 and IL-6 like cytokine. Mol Biol 2011; 45: 44-45.
34. Wang RJ, Peng RY, Gao YB, Chang GM, Xu XP, Fu KF. Jak/STAT signaling pathway of IL-11 in the protection of intestinal epithelial cells from neuron radiation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009; 25: 27-30.
35. Shan vitro human TGF-beta treatment converts CD4(+)CD25(-) T cells into induced T regulatory like cells. Vet Immunoll Immunopathol 2010; 137: 161-165.
36. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009 Mar; 15: 114-123.
37. Langrish CL, McKenzie BS, Wilson JF, de Waal Malefyt R, Kastelein RA, Cua DJ. IL-12 and IL-23: master regulators of innate and adaptive immunity. Immuno Rev 2004; 202: 96-105.
38. Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, Pak PS, Elashoff D, Reekamp K, Zhang C, Fishbein MC, Sharma S, Dubinett SM. PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Am J Transl Res 2010; 2: 356-367.
39. Lu L, Ma J, Wang X, Wang J, Zhang F, Yu J, He G, Xu B, Brand DD, Horwitz DA, Shi W, Zheng SG. Synergistic effect of TGF-beta superfamily members on the induction of FoxP3+Treg. Eur J Immunol 2010; 40: 142-152.
40. Pyzik M, Piccirllo CA. TGF-beta1 modulates FoxP3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukooc Biol 2007; 82: 335-346.
41. Allen CE, Li L, Peters TL, Leung HC, Yu A, Man TK, Gurusiddappa S, Phillips MT, Hicks MJ, Gaikwad A, Merad M, McClain KL. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol 2010; 184: 4557-4567.
42. Teruel T, Valverde AM, Benito M, Lorenzo M. Transforming growth factor beta 1 induces differentiation-specific gene expression in fetal rat brown adipocytes. FEBS Lett 1995; 364: 193-197.
43. Saito K, Ishizaka N, Hara M, Matsuzaki G, Sata M, Mori I, Ohno M, Nagai R. Lipid accumulation and transforming growth factor-beta upregulation in the kidneys of rats administered angiotensin II. Hypertension 2005; 46: 1180-1185.
44. Barbey S, Despres S, Nezelof C. Histiocytosis X. Histochemical study of intracytoplasmic lipids. Apropos of 3 cases. Pathol Biol(Paris) 1975; 23: 639-646.
45. Ross J, Najjar AM, Sankaranarayanapillai M, Tong WP, Kaluarachchi K, Ronen SM. Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine. Mol Cancer Ther 2008; 7: 2556-2565.
46. Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, Bessho F, Kudo K, Tsunematu Y, Fujimoto J, Imashuku S. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Pediatr Blood Cancer 2006; 47: 194-199.
47. Cowan RW, Singh G, Ghert M. PTHrP increases RANKL expression by stromal cells from giant cell tumor of bone. J Orthop Res 2011. [Epub ahead of print].
48. Hu T, Exton JH. Mechanisms of regulation of phospholipase D1 by protein kinase Calpha. J Biol Chem 2003; 278: 2348-2355.
49. Jenkins GM, Frohman MA. Phospholipase D: a lipid centric review. Cell Mol Life Sci 2005; 62: 2305-2316.
50. Melendez AJ, Allen JM. Phospholipase D and immune receptor signalling. Semin Immunol 2002; 14: 49-55.
51. Piazza GA, Ritter JL, Baracka CA. Lysophosphatidic acid induction of transforming growth factors alpha and beta: modulation of proliferation and differentiation in cultured human keratinocytes and mouse skin. Exp Cell Res 1995; 216: 51-64.
52. Zhou BH, Chen JS, Chai MQ, Zhao S, Liang J, Chen HH, Song JG. Activation of phospholipase D activity in transforming growth factor-betainduced cell growth inhibition. Cell Res 2000; 10: 139-149.
53. van der Bend RL, de Widt J, van Corven EJ, Moolenaar WH, van Blitterswijk WJ. The biologically active phospholipid, lysophosphatidic acid, induces phosphatidylcholine breakdown in fibroblasts via activation of phospholipase D. Comparison with the response to endothelin. Biochem J 1992; 285: 235-240.
54. Hong JH, Oh SO, Lee M, Kim YR, Kim DU, Hur GM, Lee JH, Lim K, Hwang BD, Park SK. Enhancement of lysophosphatidic acid-induced ERK phosphorylation by phospholipase D1 via the formation of phosphatidic acid. Biochem Biophys Res Commun 2001; 281: 1337-1342.
55. Jeon ES, Kim JH, Ryu H, Kim EK. Lysophosphatidic acid activates TGFBIp expression in human corneal fibroblasts through a TGF-beta1-dependent pathway. Cell Signal Feb 21. [Epub ahead of print].
56. Jeon ES, Moon HJ, Lee MJ, Song HY, Kim YM, Cho M, Suh DS, Yoon MS, Chang CL, Jung JS, Kim JH. Cancer-derived lysophosphatidic acid stimulates differentiation of human mesenchymal stem cells to myofibroblast-like cells. Stem Cells 2008; 26: 789-797.
57. Lindschau C, Quass P, Menne J, Güler F, Fiebeler A, Leitges M, Luft FC, Haller H. Glucoseinduced TGF-beta1 and TGF-beta receptor-1 expression in vascular smooth muscle cells is mediated by protein kinase C-alpha. Hypertension 2003; 42: 335-341.
58. Zhou HY, Chen WD, Zhu DL, Wu LY, Zhang J, Han WQ, Li JD, Yan C, Gao PJ. The PDE1A-PKCalpha signaling pathway is involved in the upregulation of alpha-smooth muscle actin by TGF-beta1 in adventitial fibroblasts. J Vasc Res; 47: 9-15.
59. Chow JY, Dong H, Quach KT, Van Nguyen PN, Chen K, Carethers JM. TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells. Am J Physiol Gastrointest Liver Physiol 2008; 294: G899-905.
60. Chakrabarty S, Huang S. Role of protein kinase C alpha in the induction of carcinoembryonic antigen by transforming growth factor beta 1. J Cell Physiol 1995; 164: 148-153.
61. Kim YJ, Stringfield TM, Chen Y, Broxmeyer HE. Modulation of cord blood CD8+ T-cell effector differentiation by TGF-beta1 and 4-1BB costimulation. Blood 2005; 105: 274-281.
62. Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, Shen Q, Zhu Y, Zhang Y. Metformin attenuates cardiac fibrosis by inhibiting the TGFbeta1-Smad3 signalling pathway. Cardiovasc Res 2010; 87: 504-513.
63. Brown RE, Weerasinghe P. Metformin activates AMP kinase and inhibits Gli2 expression in a human neuroblastoma cell line. Unpublished observation.
64. Lee YS, Kim YS, Lee SY, Kim GH, Kim BJ, Lee SH, Lee KU, Kim GS, Kim SW, Koh JM. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone 2010; 47: 926-937.
65. Mai QG, Zhang ZM, Xu S, Lu M, Zhou RP, Zhao L, Jia CH, Wen ZH, Jin DD, Bai XC. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J Cell Biochem 2011; 112: 2902-2909.
66. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 2010; 17: 351-360.
67. Deng XS, Wang S, Deng A, Liu B, Edgerton SM, Lind SE, Wahdan-Alaswad R, Thor AD. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle 2012; 11: 367-376.
68. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56: 641-648.